Search

Presents a bibliometric analysis of the literature in the field of Dengue as indexed the MEDLINE data which covered in the Pubmed for the period 2008 to 2017. It is noticed that total of 11826 records on literature of Dengue are covered for a period of ten years from 2008 to 2017. It is also noticed that the maximum number of records (1810) was published during year 2016, followed by 1540 in 2017 and 1520 in 2015. It was found that Journal Article (41.4%), Research Support, Non-U.S. Gov't (33.81%), Review (10.69%), Letter (3.61%), and Research Support, U.S. Gov't Non-P.H.S. (2.86%). 37 primary journals grouped in zone 1 published 1675 articles accounting for one third of the total output. Similarly the second zone comprises of 143 journals and 904 journals grouped in third zone. Of the 37 titles in zone-1, 12 are associated with United States and followed by England (9), Netherlands (5), India (4), Brazil (2), China (1), Germany (1), Japan (1), Sweden (1) and Thailand (1). In zone-1 & 2 ; out of 180 journals, 51 frequently cited journals are United States, this is followed by the countries i.e. England (33), India (19), Netherlands (11), Brazil (9), Switzerland (9), France (6), Japan (4), China (3), Egypt (3), Germany (3), Pakistan (3), Singapore (3), Colombia (2), Italy (2), Malaysia (2), Thailand (2), Argentina (1), Australia(1), Austria (1), Canada (1), Chile (1), Cuba (1), Indonesia (1), Iran (1), Jamaica (1), Mexico (1), Peru (1), Philippines (1), Poland (1), Sri Lanka (1) and Sweden (1). [ABSTRACT FROM AUTHOR]

Competing Interests: Declaration of Competing Interest Dr. Giri has received honoraria from CareVive, OncLive and research funding from Carevive Systems, Pack Health, Sanofi. Dr. Bal has served in consulting or advisory role at Adaptive Biosciences and received research funding from Amyloid Foundation.Dr. Costa received honoraria from Amgen, BMS, Janssen, Karyopharm Therapeutics, Sanofi, Takeda, served in consulting or advisory role at AbbVie, Amgen, Celgene, Karyopharm Therapeurics, speakers' bureau at Amgen, Sanofi and research funding from Janssen, Amgen and BMS. All other authors have no conflicts of interest or disclosures.